Abstracts tagged "immunology"

Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Cristina Calomarde Gomez¹, Raquel Ugena García¹, Julia Valera², Melisa Mena², Maria Esteve², Irma Casas², jose Antonio Dominguez-Benitez², lidia Carabias-Ane², isaac Nuño-Ruiz², Cristina ramo-Tello², Javier Santesmases², Lourdes Mateo Soria³ and Melania Martinez Morillo¹, ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
Abstract Number: 2464 • ACR Convergence 2023
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Erin Wilfong¹, Leslie Crofford² and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
Abstract Number: 0081 • ACR Convergence 2023
RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Cliff Rims¹, Anne Hocking¹, Sylvia Posso¹, Bernard Ng², Jeffrey Carlin³, Jane Buckner⁴ and Eddie James⁴, ¹Benaroya Research Institute, Seattle, WA, ²Veteran Affairs, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: The presence of ACPA in RA signifies an immune response toward citrullinated auto-antigens in disease pathogenesis and persistence. RA is a T cell mediated…
Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Panagiotis garantziotis¹, Georgia-Savina Moysidou², stavros doumas³, Dionysis nikolopoulos², Sofia Flouda⁴, Noemin kapsala², Anastasia Filia², George Sentis², Antonis Fanouriakis², George Bertsias⁵ and Boumpas Dimitrios⁶, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴Unit of Attikon University Hospital, Athens, Greece, ⁵Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 2465 • ACR Convergence 2023
Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen
Lindsay Bass¹, Dena Liu¹, Alberto Cisneros², Jennifer Young-Glazer², Leslie Crofford³, Erin Wilfong² and Rachel Bonami², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
Abstract Number: 0082 • ACR Convergence 2023
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
Adam Cartwright¹, Foram Desai², Sophia Nguyen², Alexandra Trouilloud², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Chris King², Debora Bonenfant¹, Sharon Townson², Owen Wallace², Filip Janku², Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 1586 • ACR Convergence 2023
Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing
Zachary Peters¹, Lindsay Mendyka², Sicong Shan¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We…
Abstract Number: 1986 • ACR Convergence 2023
Deep Immunophenotyping of Osteoarthritis Patients Demonstrates Baseline Alterations in Monocyte Populations in OA, Dendritic Cell Subpopulations Among Radiographic Progressors, and Th17 Cells Among Pain Progressors
Gabby Dyson¹, Montana Barrett² and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Guthrie, OK
Background/Purpose: Previous studies have suggested low-level chronic inflammation plays a key role in knee osteoarthritis (OA) development and progression. In the present study, we set…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Timothy Burwell¹, Jeffrey Hall¹, Suzanne Cole², Sarah Tursi¹, Isabelle Baribaud³, Kyle Bednar¹, Naresh Kumar¹, Julie Carman¹, Navin Rao² and Edith Janssen², ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…
Abstract Number: 0087 • ACR Convergence 2023
Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients
Kathryne Marks¹, Anvita Singaraju², Runci Wang³, Ifeoluwakiisi Adejoorin¹, Miriam Fein², Michael Postow⁴, Karmela Kim Chan², Anne Bass⁵, Laura Donlin² and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies used to treat cancer can induce immune related Adverse events (irAEs) such as ICI-induced arthritis (ICI-arthritis). We have previously…
Abstract Number: 0692 • ACR Convergence 2023
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Johannes Nowatzky¹, Ziyan Lin², Yesim Ozguler³, Alireza Khodadadi-Jamayran², Didar Ucar⁴, Aristotelis Tsirigos⁵, Gulen Hatemi⁶ and Olivier Manches⁷, ¹NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, ²NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁵NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France
Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…

« Previous Page
1
…
5
6
7
8
9
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].